A Chemotherapy-Free Regimen of Tucatinib and Trastuzumab Shows Antitumour Activity with Durable Responses in Patients with HER2-mutated MBC By Ogkologos - January 29, 2025 520 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the SGNTUC-019 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO’s Special Consultative Status with United Nations Economic and Social Council (UN ECOSOC) Confirmed Until 2028 EMA Recommends Extension of Indications for Selumetinib ESMO Calls for Urgent Changes to the in Vitro Diagnostic Medical Devices Regulation (IVDR) in Order to Safeguard Cancer Research in Europe MOST POPULAR Childhood cancer survivors at greater risk of ill health November 22, 2021 Studies Delve Deep into the Protein Machinery of Cancer Cells November 4, 2021 Mom Gives ‘Elf On The Shelf’ A Wheelchair For Daughter With... December 23, 2021 What to Know About Treatment Options Before and After Surgery for... November 7, 2023 Load more HOT NEWS Can mRNA Vaccines Help Treat Cancer? Sublobar Resection Noninferior to Lobectomy in Terms of DFS Among Patients... Enhancements to NCI’s SEER Program Creating New Research Opportunities FDA Approves a Fixed-Dose Combination of Nivolumab and Relatlimab for Unresectable...
